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acceptance of stroke prophylactic treatment. Interestingly, no single patients char-
acteristics changed the fact that AF patients were willing to accept a non-zero risks
of bleeding in exchange for prevention of disabling strokes.
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OBJECTIVES: To assess item analysis and dimensional validity of a new question-
naire developed to measure Satisfaction with medical care in patients with atrial
fibrillation, in order to accomplish item reduction. METHODS: The initial instru-
ment was composed by 37 items, arranged in 6 dimensions: 1- Efficacy (4 items), 2-
Ease and convenience (7 items), 3- Impact on daily activities (11 items), 4- Satisfac-
tion with medical care (6 items), 5- Medication undesired effects (6 items), and 6-
Overall satisfaction (4 items). Items and dimensions where extracted from review-
ing previous English instruments, 3 focus groups with chronic patients, and a panel
composed by 8 experts. Additionally 3 Visual Analog Scales (VAS) measuring Qual-
ity of Life, Effectiveness and Overall Satisfaction were applied. A convenience sam-
ple of 118 patients was used. Classic psychometric theory item analysis tech-
niques, exploratory factor and confirmatory factor analysis, test-retest and
correlation with VAS scales were used. RESULTS: The questionnaire was reduced
in length to 25 items, but the Impact dimension had to be divided in 2 dimensions:
Treatment inconvenience and Treatment Control. The reduced version presents
an overall Cronbach alpha of 0.861, with acceptable dimensional reliabilities (0.764-
0.908). Individual dimensions were well formed and correlated in different degrees,
being the dimension of Satisfaction with medical care the most independent one.
Test-retest correlations were high (0.784-0.965) and correlations with VAS scales
were meaningful. CONCLUSIONS: The 25-item questionnaire shows good reliabil-
ity and validity to assess satisfaction with medical care in patients with atrial
fibrillation. Further research is needed to examine if the questionnaire could be
generalized to different populations of patients with atrial fibrillation.
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OBJECTIVES: To describe demographical and medical characteristics of patients
treated with bi- or multi- antihypertensive therapies and to outline the link be-
tween therapeutic scheme, blood pressure control and patients co morbidities.
METHODS: A retrospective study was undertaken, based on the IMS Lifelink Elec-
tronic Medical Records database (Disease Analyzer), investigating age, gender,
blood pressure control and co morbidities according to the number and type of
associated antihypertensive therapies. RESULTS:A total of 13,618 patients, treated
by bi- or multi- antihypertensive therapies and for whom blood pressure levels
were available have been included in a 2008 study cohort (mean age  66.8, 48%
men). Respectively 39% and 58% of patients had a controlled blood pressure de-
pending on the threshold of the control (140/90 or 140/90), showing the im-
portance of the precise threshold in real-life. Respectively 1.5% and 0.3% of patients
had a blood pressure of over 160/100 and over 180/110. Significantly more patients
(p 0.05) have a controlled blood pressure under tri-therapy (41.6%/64.2% accord-
ing to the two previous thresholds) rather than under bi-therapy (37.9%/57.8%), but
no control difference is seen in patients treated by tri-therapy vs 4 or more. 59.4%
of patients have at least one cardiovascular, renal or diabetic co morbidity; a sta-
tistical link has been shown between the patient number of co morbidities and the
number of associated antihypertensive drugs in the treatment scheme.
CONCLUSIONS:The number of antihypertensive associated in a treatment scheme
increases with the patient co morbidity level. Despite the use of bi- or multi-ther-
apies, Sixty-one percent of patients who are being prescribed several antihyper-
tensive drugs do not have a controlled blood pressure (140/90); prescribing 4 or
more associated antihypertensive does not seem to increase the percentage of
controlled patients.
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OBJECTIVES: Disease definitions can evolve over time, and may be influenced by
the prevailing evidence base/understanding of the condition. Without a common
definition, significant scope exists for unanticipated impact on the health care
system and patients. We investigated this through assessment of primary non-
familial hypercholesterolaemia (PN-FH) in UK adults. METHODS: The 2007 NICE
Technology Appraisal of ezetimibe reported prevalence of PN-FH from two differ-
ent sources: 1) a 1999 publication reporting prevalence at 4.2%, based on a defini-
tion that PN-FH was “responsible for all cholesterol levels above the 95th percentile not
accounted for by a familial cause”; and 2) a 2003 article, reporting a range of 20-80%,
using a contemporary definition of PN-FH: a cholesterol level above a desirable/
recommended level, where familial and secondary causes have been excluded. We
used the older definition (4.2%) and lower bound of the range (20%) to estimate the
prevalence of PN-FH in UK adults. Simvastatin 40mg costs and Heart Protection
Study (HPS) results were used to estimate drug acquisition costs and number of
events prevented. RESULTS: At prevalence rates of 4.2% vs. 20%, 2.1m or 9.8m UK
adults have PN-FH. Accounting only for those diagnosed and requiring treatment
(30% of the population), the 1999 definition (4.2%) estimates 618,940 patients re-
quiring medication vs. 2,947,332 using the lower bound of the modern definition
(20%). The respective 5-year (mean follow-up in HPS) drug acquisition costs would
vary from £48.0m to £228.6m, and be expected to prevent 9,414 or 44,826 vascular
deaths, and 33,301 or 158,575 major vascular events (including 7,241 or 34,481
non-fatal MI’s and 8,022 or 38,201 non-fatal strokes). CONCLUSIONS: The impor-
tance of an accurate and contemporary definition of the condition under investi-
gation is paramount. Alternative rates available to NICE are associated with differ-
ences in 5-year drug cost of at least £180m, over 35,000 fewer vascular deaths and
125,000 fewer vascular events.
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OBJECTIVES: Egypt has long been trying to reform health care reimbursement
mechanisms. Currently, health care out-of-pocket expenditure in Egypt is almost
72%, with over 30% of total health care expenditure (THE) dedicated to medica-
tions1. At the same time, hypertension is becoming one of the main killers of
Egyptian adults. With an inefficient national scheme for financial protection
against chronic illnesses, anti-hypertensive medications are becoming a burden
for the Egyptian household budget. This research aims to examine factors affecting
affordability of anti-hypertensive medications in Egypt under current reimburse-
ment systems. METHODS: This research will use anti-hypertensive drugs sales
data as a proxy to identify the pattern of usage of antihypertensive drugs in differ-
ent regions of Egypt, under the different reimbursement systems (including out-
of-pocket). A trend (if any) will be drawn over time, to identify the impact of chang-
ing reimbursement policies, and the increase of medication prices on anti-
hypertensive drugs usage. For this purpose, we will look into sales/ dispensing data
from main health care providers; Ministry of Health & Population (MoHP), Health
Insurance Organization (HIO), and retail pharmacies’ sales data in the different
regions of Egypt. As well as demographic characteristics, health care services de-
livery models in each region, and the average annual income of individuals. Dif-
ferences between the different regions of Egypt, & factors affecting them, shall also
be highlighted. RESULTS: Weak and fragmented health insurance system, leads to
a high out-of-pocket drug expenditure, affecting affordability of, & subsequently
access to, anti-hypertensive medications. CONCLUSIONS: Efficient drug reim-
bursement systems should be improved to achieve better patient access to chronic
illnesses’ medication.
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OBJECTIVES: In May 2012, generic atorvastatin has become available in Belgium.
This study examines the impact of market entry of generic atorvastatin on Belgian
statin market and on cost-effectiveness of statin therapy. METHODS: Using IMS
Health data, the Belgian 2000-2011 statin market was analyzed in terms of total
expenditure, annual price of statin treatment, and number of patients. Also, a
simulation analysis projected market shares in the Belgian statin market from 2012
to 2015 following market entry of generic atorvastatin. This analysis was based on
three scenarios regarding the number of patients taking specific statins. Savings
associated with an atorvastatin price reduction of 50%-70% were calculated. A
literature review of economic evaluations was conducted to assess the cost-effec-
tiveness of generic atorvastatin. RESULTS: Statin expenditure more than doubled
from €113 million in 2000 to €285 million in 2011, mainly as a result of higher
expenditure on atorvastatin and rosuvastatin. Although the number of patients
treated with simvastatin increased by nearly 800% during 2000-2011, the resulting
increase in expenditure was partially offset by price reductions due to generic
competition and a simvastatin tender. The simulation analysis indicated that ator-
vastatin will become the dominant product in the Belgian statin market (market
share by expenditure of 47%-66% by 2015). Annual savings were projected to attain
€108.6-€153.7 million for a 50% reduction in the atorvastatin price and €152.0-€215.2
million for a 70% price reduction. The literature suggests that generic atorvastatin
is cost-effective as compared to simvastatin and becomes more cost-effective at
higher daily doses. The limited evidence about the cost-effectiveness of rosuvas-
tatin as compared with generic atorvastatin is inconclusive. CONCLUSIONS: Ge-
neric atorvastatin is cost-effective as compared to simvastatin, is projected to be-
come the dominant product in the Belgian statin market and is expected to
generate substantial savings to health care payers.
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